Harvest Portfolios Group Inc. Sells 31,935 Shares of Eli Lilly and Company $LLY

Harvest Portfolios Group Inc. trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 11.4% during the fourth quarter, HoldingsChannel reports. The fund owned 247,389 shares of the company’s stock after selling 31,935 shares during the quarter. Eli Lilly and Company comprises approximately 4.6% of Harvest Portfolios Group Inc.’s holdings, making the stock its 3rd largest position. Harvest Portfolios Group Inc.’s holdings in Eli Lilly and Company were worth $265,864,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $35,991,000. Hartford Funds Management Co LLC raised its holdings in shares of Eli Lilly and Company by 74.6% during the fourth quarter. Hartford Funds Management Co LLC now owns 3,214 shares of the company’s stock valued at $3,456,000 after buying an additional 1,373 shares during the last quarter. McKinley Carter Wealth Services Inc. raised its holdings in shares of Eli Lilly and Company by 17.9% during the fourth quarter. McKinley Carter Wealth Services Inc. now owns 7,206 shares of the company’s stock valued at $7,745,000 after buying an additional 1,096 shares during the last quarter. Flynn Zito Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 117.3% during the fourth quarter. Flynn Zito Capital Management LLC now owns 2,143 shares of the company’s stock valued at $2,304,000 after buying an additional 1,157 shares during the last quarter. Finally, Integral Investment Advisors Inc. lifted its holdings in Eli Lilly and Company by 3.7% in the fourth quarter. Integral Investment Advisors Inc. now owns 4,075 shares of the company’s stock worth $4,379,000 after purchasing an additional 144 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 3.0%

Shares of Eli Lilly and Company stock opened at $1,017.68 on Wednesday. The stock’s fifty day moving average is $940.54 and its 200-day moving average is $1,000.84. The firm has a market capitalization of $958.39 billion, a PE ratio of 36.15, a price-to-earnings-growth ratio of 1.07 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 24.58%.

Analyst Ratings Changes

LLY has been the subject of several research analyst reports. Wolfe Research reaffirmed an “outperform” rating and issued a $1,325.00 price objective on shares of Eli Lilly and Company in a report on Monday, May 4th. Guggenheim reaffirmed a “buy” rating and issued a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Finally, Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,218.33.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and market commentary continue to highlight Eli Lilly’s leadership in the obesity boom, with strong sales momentum in key products such as Mounjaro and broader confidence that the company still has room to run. Article Title
• Positive Sentiment: Stat News reported that Eli Lilly tops prominent rankings for pharma R&D performance, reinforcing the view that the company’s pipeline and innovation engine remain among the best in the industry. Article Title
• Positive Sentiment: Eli Lilly also announced it completed a key olomorasib drug-interaction study, which helps clarify next steps for its KRAS pipeline and supports the long-term growth story beyond obesity drugs. Article Title
• Neutral Sentiment: The company will participate in Bernstein’s Strategic Decisions Conference later this month, a routine investor-relations event that could provide more details on strategy and pipeline updates. Article Title
• Negative Sentiment: The U.S. Supreme Court declined to hear Eli Lilly’s appeal in a Medicaid whistleblower case, leaving in place a roughly $194 million award and keeping legal/compliance risk in focus. Article Title
• Negative Sentiment: Related coverage noted that the ruling could raise scrutiny around Medicaid rebates and dividend implications, adding a modest overhang even as the core business remains strong. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.